医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Appoints Dr. Sripada Chandrasekhar as President and Global Head of Human Resources

2013年08月13日 AM12:55
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s has announced the appointment of Dr. Sripada Chandrasekhar as the President and Global Head of Human Resources; he will also be a member of Dr. Reddy’s Management Council. With over 30 years of experience, Dr. Chandrasekhar brings a rare blend of experience across India’s leading firms in Public, Private and Multi-National sectors – both in the early economy areas of steel and manufacturing as well as in the more recent domains of Telecom, IT Services and Consulting.

Prior to joining Dr. Reddy’s, Dr. Chandrasekhar worked with IBM in India as Vice President and Head of Human Resources for the India/South Asia region. He was a key member of their India Leadership Team and a Director on the Board of IBM India.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to:

www.drreddys.com

CONTACT

Dr. Reddy’s Laboratories Ltd.
Investors
and Financial Analysts:

Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak
Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan
Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
or
Media:
S
Rajan, +91-40-49002445
rajans@drreddys.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates